LATS2 and BRAF

Number of citations of the paper that reports this interaction (PubMedID 28205554)
32

Data Source:
BioGRID (fluorescent resonance energy transfer)

		LATS2	BRAF
Description		large tumor suppressor kinase 2	B-Raf proto-oncogene, serine/threonine kinase
Image
GO Annotations	Cellular Component	Spindle Pole Nucleus Cytosol Centriolar Satellite	Nucleus Mitochondrion Cytosol Plasma Membrane Intracellular Membrane-bounded Organelle
	Molecular Function	Protein Serine/threonine Kinase Activity Protein Binding ATP Binding Metal Ion Binding	Protein Kinase Activity Protein Serine/threonine Kinase Activity Calcium Ion Binding Protein Binding ATP Binding Small GTPase Binding Identical Protein Binding
	Biological Process	G1/S Transition Of Mitotic Cell Cycle Protein Phosphorylation Hormone-mediated Signaling Pathway Peptidyl-serine Phosphorylation Hippo Signaling Intracellular Signal Transduction Positive Regulation Of Apoptotic Process Negative Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity Regulation Of Organ Growth Cell Division Negative Regulation Of Canonical Wnt Signaling Pathway	MAPK Cascade Activation Of MAPKK Activity Protein Phosphorylation Animal Organ Morphogenesis Positive Regulation Of Gene Expression Positive Regulation Of Glucose Transmembrane Transport Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Apoptotic Process Positive Regulation Of ERK1 And ERK2 Cascade Trehalose Metabolism In Response To Stress Cellular Response To Calcium Ion Establishment Of Protein Localization To Membrane
Pathways		Signaling by Hippo	Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants
Drugs			Sorafenib XL281 N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib
Diseases			Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer Malignant melanoma
GWAS		3-month functional outcome in ischaemic stroke (modified Rankin score) ( 30796134)	anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Bipolar disorder ( 31043756) Cerebrospinal fluid t-tau:AB1-42 ratio ( 26252872) Cerebrospinal T-tau levels ( 26252872) Mild influenza (H1N1) infection ( 26379185) Response to Vitamin E supplementation ( 22437554) Type 2 diabetes ( 28869590)
Interacting Genes		71 interacting genes: ABL1 AJUBA AKT1 AMOT ARAF ARNT AURKA AURKB BECN1 BRAF CBLC CCND2 CCNE1 CD44 CDK2 CDK4 CDK6 CDKN1A CDKN2A CDKN2B CDKN2C CHEK1 CHEK2 CTNNB1 DYRK1A EPHA2 ERBB2 EZH2 FGFR4 FHL3 FZR1 GLIS1 GLIS2 GRAP2 GRM1 HGF HIF1A KAT2A KDELR2 KIF23 MAP2K3 MAP2K5 MAP3K5 MAPK14 MDM4 MET MOB3A MOB3B MOB3C MOB4 MYC NF2 NFIC PDGFRA RAF1 RASSF1 RELA SMAD2 SNAI1 STK11 STK3 STK4 SUZ12 TAZ TEAD2 TP53 TSC1 WWTR1 YAP1 YWHAG YWHAZ	39 interacting genes: AKT1 ARAF AURKA BAD CCDC88A HRAS ITCH KRAS LATS2 MAP2K1 MAP2K2 MAP2K3 MAP2K6 MAPK1 MRAS NANOG OIP5 PAK2 PPP2CA PPP2R2A PRKACA PRKCE RAF1 RAP1A RAP1GAP RASSF1 RHEB SFN SGK1 SPRY2 STK11 TERF1 TERT UBE2L3 YWHAB YWHAG YWHAH YWHAQ YWHAZ
Entrez ID		26524	673
HPRD ID		07277	01264
Ensembl ID		ENSG00000150457	ENSG00000157764
Uniprot IDs		A0A024RDM3 Q9NRM7	A0A2R8Y8E0 P15056
PDB IDs		4ZRI	1UWH 1UWJ 2FB8 2L05 3C4C 3D4Q 3IDP 3II5 3NY5 3OG7 3PPJ 3PPK 3PRF 3PRI 3PSB 3PSD 3Q4C 3Q96 3SKC 3TV4 3TV6 4CQE 4DBN 4E26 4E4X 4EHE 4EHG 4FC0 4FK3 4G9C 4G9R 4H58 4JVG 4KSP 4KSQ 4MBJ 4MNE 4MNF 4PP7 4R5Y 4RZV 4RZW 4WO5 4XV1 4XV2 4XV3 4XV9 4YHT 5C9C 5CSW 5CSX 5CT7 5FD2 5HI2 5HID 5HIE 5ITA 5J17 5J18 5J2R 5JRQ 5JSM 5JT2 5VAL 5VAM 5VR3 5VYK 6B8U 6CAD 6N0P 6N0Q 6NSQ 6NYB 6PP9 6Q0J 6Q0K 6Q0T 6U2G 6U2H 6UAN
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?